62 results about "Patient affected" patented technology

A system for management of a chronic medical condition generally comprises a plurality of networked physical and/or virtual elements configured to cooperate to aid in management of a chronic medical condition of a patient. The system is configured to provide a primary caregiver with current data relating to the patient's medical condition, and to allow the caregiver to provide appropriate changes to the patient's treatment via an analyte detection meter. The meter is generally configured to calculate a treatment dosage by combining a plurality of patient-affected and caregiver-affected variables. One embodiment relates to a system for management of a diabetic condition in which the primary caregiver is provided with glucose concentration data as well as other information relating to a diabetic condition. The primary caregiver can then make appropriate changes to correction factors to be implemented in an analyte detection meter which is configured to calculate an insulin dosage.

The disclosure provides methods, devices and systems for recovering motor control of an area in the body of a patient affected by a neurological disorder. In some embodiments, a device stimulates a substitute site for the affected area thereby recovering the motor control of the affected area, wherein the device is volitionally controlled by said patient.

The invention relates to a customized abutment assembly and a preparation method thereof. The assembly comprises an abutment body, a fixed bolt connected between an implant body and the abutment body and an anti-loose pad, wherein the abutment body comprises a dental crown connecting section, a gum penetrating section and an implant body connecting section, and a stepped bore is formed in the abutment body; the abutment angle alpha and abutment shape of the abutment body are formed according to angles and shapes of a patient affected tooth and the implant body, so as to adapt to the angles and shapes of the patient affected tooth and the implant to obtain the customized abutment; the abutment angle alpha is the included angle between the center line of the dental crown connecting section and the center line of the implant body connecting section. The abutment assembly is formed by means of 3D (three-dimensional) scanning, CAD (computer aided design) modeling, 3D printing and thermal treatment, can sufficiently meet the customized requirements of different patients, and is advantageous to improve the aesthetic effect of teeth and better accords with physiological functions of teeth. Moreover, hospitals need not store massive products for clinical option, and the medical cost is furthest saved.

The present invention concerns in vitro methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family based on a resistance expression signature, kits for performing the methods, and methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment of a cancer with the molecule of the taxoid family.

The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy.

The invention relates to a method for the identification of patients affected by Systemic Sclerosis (SSc) (early, limited cutaneous, diffuse forms) or Systemic Lupus Erythematosus (SLE). Among SSc and SLE patients, this method allows identification of presence of vascular ulcerations in SSc, and Raynaud's phenomenon in SLE, respectively.

The invention consists of a bent flat member, which, properly inserted in the vagina, may be used to help a patient affected with rectocele (hernia) eliminate fecal matter, which otherwise may remain in the pocket formed by the hernia, and cause medical problems. The instrument is washable and may be indefinitely re-used by the patient.

The present disclosure describes systems and methods for using patient-specific genomic information to optimize or de-risk therapy for the patient. A user may identify a medication for consideration for prescription to a patient, and a genetic variant of the patient affecting a first protein. An analyzer may identify a second medication targeting the first protein, and may retrieve adverse event data from an adverse event database for patients co-medicated with both the first medication and second medication. The analyzer may determine, based on rates of adverse events, the likelihood of an adverse event occurring through co-medication of the first medication and second medication. Based on the likelihood, and based on a correspondence or non-correspondence between a protein activation characteristic of the first medication and the effect of the genetic variant of the patient, the analyzer may indicate or contra-indicate the first medication for the patient.

The invention discloses an intensity adjustment radiotherapy planning dosiology indication item prediction method comprising the following steps: (1) collecting effective intensity adjustment radiotherapy plan data to form a case database; (2) calculating the distance-distribution map (dDTH) of the patient-affected organ from the target area as the geometric feature of the patient; (3) determiningan interested dose-learning index item; (4) establishing a linear correlation model between the geometric feature of the patient and the dosiology feature; (5) constructing a target function; (6) solving a target function to train an associated model by taking the geometric feature and the dosiology feature as the input by means of the improved bagging integrated learning algorithm; and (7) predicting the planned dosiology index value of the new patient by means of the linear correlation model. According to the invention, the method can achieve the dosiology indication item prediction of theintensity adjustment radiotherapy plan, and can be applied to quality control.

The invention relates to the fields of biomedical engineering, computer technology and communication, and specifically discloses an accurate positioning method of a rehabilitation FES signal for stroke patients. The method comprises the steps of wearing a dynamic exoskeleton, defining sensor parameters, performing healthy joint movement, recording exercise data of a healthy joint and the myoelectric signal data of adjacent limbs, and calculating the corresponding motion data of an affected joint and the action time and action point of the FES. The accurate positioning method determines a functional electrical stimulation site and a timing of the affected joint through the healthy joint motion of the patients, instead of determining by the experience of a rehabilitation engineer, by using the principle of time-lapse mirroring, each patient can find electrical stimulation time and action positions suitable for own physical conditions, the FES stimulation on the patients makes the actionof the patient affected joint closer to the action of normal limbs, which can better improve the activation of the brain mirror neurons and promote the rehabilitation of the patients, and the method can help the stroke patients to correct gait during the rehabilitation process to a certain extent.

The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 (LINE-1) repetitive DNA sequences and/or the concomitant methylation profile of specific groups of genes defined as methylation signature.

The invention provides a remote auscultation method and system; a receiver and a pickup collect sound information of a patient affected part; an audio frequency converter converts the sound information collected by the receiver and the pickup into a digital signal, and the digital signal is emitted by a signal emission module; a signal reception module receives the digital signal emitted by the signal emission module, the received digital signal is converted into sound information, and the sound information is sent to a doctor. The signal reception module receives the signal through Bluetooth or a WIFI module. The method and system can realize remote auscultation.

The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.

The invention relates to an escherichia coli recombinate expression method of mycobacterium tuberculosis Rv 2837c active protein and applications thereof. The mycobacterium tuberculosis Rv 2837c protein gene is cloned into a prokaryotic expression vector Pet28a+, and the gene is named as pET-CnpB. A Ni ion affinity chromatography method is adopted to obtain purified Rv2837c active protein. The recombinant Rv2837c protein can be used to detect the serum of animals and patients affected by mycobacterium tuberculosis. The recombinant Rv2837c protein can induce high level body fluid and cellular immunologic response of mouse, and can be used to develop novel subunit vaccine of tuberculosis. So Rv2837c protein has a good application prospect. The invention relates to the applications of the active recombinant protein in the preparation of drugs or preparations for diagnosing and preventing tuberculosis.

The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with a high-MAP3K8 ovarian cancer (i.e. an ovarian cancer with a high expression and/or activity level of MAP3K8) to a treatment comprising at least one MEK inhibitor. The invention also further relates to a MEK inhibitor for use in the treatment of high-MAP3K8 ovarian cancer and kit that can be used in the methods of the invention.

The present invention relates to a method for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor such as sunitinib. More specifically, the method of the invention comprises a step of determining the expression level of one marker consisting of the FSHR in a biological sample obtained from said patient, and more specifically in the blood endothelial cells from the tumors.

The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a cancer, in particular with a breast cancer, a lung cancer or other primary cancer, said methods comprising the step of detecting a higher expression level of FERMT1 gene in a tumour sample compared to a control reference values. The invention further relates to inhibitors of FERMT1 expression and their uses in the treatment of cancer or metastasis.

The invention discloses a cycle ergometer used for lower limb dysfunction patient rehabilitation training and relates to the technical field of medical apparatus and instruments. The cycle ergometer comprises a pedal which is fixedly connected with an ankle or foot orthotics device by a fastener; the ankle or foot orthotics device comprises a shin rear plate, a fixed band and a foot support; the foot support comprises a foot bottom plate which is integrally molded, side baffles on two sides of the foot bottom plate and a front baffle on the front edge of the foot bottom plate; the height h of the foot bottom plate is 3-4 cm; an outer side heightening taper liner is arranged in the foot support and is close to the outer side baffle; the outer side heightening taper liner is an inclined cushion block which is downwards inclined from the outer side baffle to the center of the plate surface of the foot bottom plate; the slant angle alpha of the inclined cushion block is 5-10 degrees. According to the invention, the problems that when a patient carries out rehabilitation exercise on the cycle ergometer, a foot easily slides down from the pedal, and affected limb hip joint extorsion, ankle joint plantar flexion, strephenopodia state and the like which are not beneficial to patient affected limb correction and rehabilitation occur during training are solved.

The present invention relates to methods for identifying the susceptibility or predisposition of an individual to schizophrenia SZ) or to clusters of symptoms associated thereof. Particularly, the tests can be performed before or after the disorders appear. More particularly, the present invention relates to the determination of epistatic effect of at least two genotype related loci. In addition, the invention provides tests for the classification of different subtypes predicting severity of illness of patients affected by or predisposed to SZ or associated clusters of symptoms.